An exciting avenue for future research would be to test whether breast tumors with high CA20 are more susceptible to E2F1 or SHH inhibitors, drugs targeting DNA repair mechanisms (e.g., PARP inhibitors), chemotherapeutics that target the cell cycle (e.g., taxanes), or centrosome declustering drugs (such as griseofulvin, noscapinoids, PJ34, and KifC1/HSET inhibitors), which preferentially eliminate cells with CA by forcing them to construct a multipolar spindle during mitosis16–20. Here, SHH is linked to breast neoplasm.